

Committee on Energy and Commerce
U.S. House of Representatives
 Witness Disclosure Requirement - "Truth in Testimony"
 Required by House Rule XI, Clause 2(g)

1. Your Name: MICHAEL CARUSI		
2. Are you testifying on behalf of the Federal, or a State or local government entity?	Yes	No <input checked="" type="checkbox"/>
3. Are you testifying on behalf of an entity that is not a government entity?	<input checked="" type="checkbox"/>	No
4. Other than yourself, please list which entity or entities you are representing: NATIONAL VENTURE CAPITAL ASSOCIATION (NVCA)		
5. Please list any Federal grants or contracts (including subgrants or subcontracts) that you or the entity you represent have received on or after October 1, 2011: NONE.		
6. If your answer to the question in item 3 in this form is "yes," please describe your position or representational capacity with the entity or entities you are representing: I AM A MANAGING DIRECTOR OF ADVANCED TECHNOLOGY VENTURES (ATV), AN NVCA MEMBER, AND LIGHTSTONE VENTURES (LSV).		
7. If your answer to the question in item 3 is "yes," do any of the entities disclosed in item 4 have parent organizations, subsidiaries, or partnerships that you are not representing in your testimony?	Yes	No <input checked="" type="checkbox"/>
8. If the answer to the question in item 3 is "yes," please list any Federal grants or contracts (including subgrants or subcontracts) that were received by the entities listed under the question in item 4 on or after October 1, 2011, that exceed 10 percent of the revenue of the entities in the year received, including the source and amount of each grant or contract to be listed: NONE		
9. Please attach your curriculum vitae to your completed disclosure form. SEE ATTACHED.		

Signature:



Date:

6/6/14



Mike Carusi

Mike is a General Partner and Team Leader of Lightstone Ventures (LSV) and focuses on investments in the biopharmaceutical and medical device sectors. He is based in the firm's Palo Alto, CA office, where he also serves as a General Partner at Advanced Technology Ventures (ATV). His representative investments include Altura Medical, Ardian (acquired by Medtronic), EndoGastric Solutions, GI Dynamics (ASX: GID), Holaira, MicroVention (acquired by Terumo), Plexxikon (acquired by Daiichi Sankyo), PowerVision, Second Genome, and TranS1 (NASDAQ: TSON).

Featured on the Forbes Midas List of top technology and life science investors, Mike is a recognized thought leader in the industry and a frequent speaker at healthcare conferences. He serves as a Lecturer at the Amos Tuck School of Business Administration at Dartmouth College where he also sits on the Tuck MBA Advisory Board. Previously, Mike was a faculty member of the Stanford Biodesign Emerging Entrepreneurs Forum and an advisory board member to the UCSF/Berkeley Venture Innovation Program.

Earlier in his career, Mike served as the Director of Business Development for Inhale Therapeutic Systems (now Nektar Therapeutics, NASDAQ: NKTR), a venture-backed pulmonary drug delivery company that went public in 1994. At Inhale, Mike led partnering activities with a number of pharmaceutical and biotechnology companies in the U.S., Europe, and Japan. Mike also was a Principal at The Wilkerson Group, a leading management consulting firm focused exclusively on healthcare. At The Wilkerson Group, Mike helped establish the firm's offices in London and San Francisco.

Education:

M.B.A. from the Amos Tuck School of Business Administration at Dartmouth College
B.S. Mechanical Engineering from Lehigh University.

Representative Investments

- Altura Medical
- Ardian
- EndoGastric Solutions
- GI Dynamics
- Holaira
- MicroVention
- Plexxikon
- Powervision
- Second Genome
- TranS1